choline has been researched along with Prostatic Neoplasms, Castration-Resistant in 24 studies
Prostatic Neoplasms, Castration-Resistant: Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Viable bone metastases and osteoblastic change induced by the treatment effect were identified in 53 (94." | 5.62 | Assessment of the viability and treatment response of bone metastases in patients with metastatic castration-resistant prostate cancer using choline PET/CT. ( Hanasaki, T; Kanematsu, A; Kawanaka, Y; Kitajima, K; Komoto, H; Nagasawa, S; Shimatani, K; Taguchi, M; Yamada, Y; Yamakado, K; Yamamoto, S, 2021) |
| "Two patients with castrate-resistant prostate cancer and symptomatic skeletal metastases underwent F-fluorocholine PET/CT prior to treatment with Ra-dichloride to reveal additional active lesions in the prostate gland and lymph nodes." | 3.85 | Soft Tissue Response on 18F-Fluorocholine PET/CT in Metastatic Castrate-Resistant Prostate Cancer Treated With 223Ra-Dichloride: A Possible Abscopal Effect? ( Coel, MN; Kwee, SA; Lim, J, 2017) |
| "Prostate cancer is a very heterogeneous disease, and contemporary management is focused on identification and treatment of the prognostically adverse high-risk tumors while minimizing overtreatment of indolent, low-risk tumors." | 2.61 | Multimodality Imaging of Prostate Cancer. ( Burger, IA; Ghafoor, S; Vargas, AH, 2019) |
| "Viable bone metastases and osteoblastic change induced by the treatment effect were identified in 53 (94." | 1.62 | Assessment of the viability and treatment response of bone metastases in patients with metastatic castration-resistant prostate cancer using choline PET/CT. ( Hanasaki, T; Kanematsu, A; Kawanaka, Y; Kitajima, K; Komoto, H; Nagasawa, S; Shimatani, K; Taguchi, M; Yamada, Y; Yamakado, K; Yamamoto, S, 2021) |
| "Forty-nine consecutive prostate cancer patients diagnosed with oligometastatic recurrence on Ch-PET have been prospectively treated." | 1.51 | Outcomes after a first and/or second salvage treatment in patients with oligometastatic prostate cancer recurrence detected by (18-F) choline PET-CT. ( Ahtamon, A; Bilbao, P; Cacicedo, J; Casquero Ocio, F; Fernandez, I; Garcia-Olaverri, J; Gomez-Iturriaga, A; Llarena, R; Ortiz de Zarate, R; Ost, P; Rodeño, E, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 18 (75.00) | 24.3611 |
| 2020's | 6 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, H | 2 |
| Orme, JJ | 2 |
| Abraha, F | 2 |
| Stish, BJ | 1 |
| Lowe, VJ | 3 |
| Lucien, F | 2 |
| Tryggestad, EJ | 2 |
| Bold, MS | 2 |
| Pagliaro, LC | 2 |
| Choo, CR | 1 |
| Brinkmann, DH | 1 |
| Iott, MJ | 1 |
| Davis, BJ | 1 |
| Quevedo, JF | 1 |
| Harmsen, WS | 2 |
| Costello, BA | 1 |
| Johnson, GB | 2 |
| Nathan, MA | 1 |
| Olivier, KR | 1 |
| Pisansky, TM | 1 |
| Kwon, ED | 2 |
| Dong, H | 2 |
| Park, SS | 2 |
| Kim, Y | 1 |
| Qian, J | 1 |
| Arafa, A | 1 |
| Thapa, I | 1 |
| Kosti, J | 1 |
| Ali, H | 1 |
| Alamiri, J | 1 |
| Britton, CJ | 1 |
| Ahmed, ME | 1 |
| Andrews, JR | 1 |
| Higa, JL | 1 |
| Dundar, A | 1 |
| Karnes, RJ | 1 |
| Kwon, E | 1 |
| Kendi, AT | 1 |
| Ghafoor, S | 1 |
| Burger, IA | 1 |
| Vargas, AH | 1 |
| Annovazzi, A | 1 |
| Faiella, A | 1 |
| Pescarmona, E | 1 |
| Sanguineti, G | 1 |
| Sciuto, R | 1 |
| Filippi, L | 1 |
| Basile, P | 1 |
| Schillaci, O | 1 |
| Bagni, O | 1 |
| Kitajima, K | 1 |
| Yamamoto, S | 1 |
| Kawanaka, Y | 1 |
| Komoto, H | 1 |
| Shimatani, K | 1 |
| Hanasaki, T | 1 |
| Taguchi, M | 1 |
| Nagasawa, S | 1 |
| Yamada, Y | 1 |
| Kanematsu, A | 1 |
| Yamakado, K | 1 |
| Smith, TAD | 1 |
| Phyu, SM | 1 |
| Alzyoud, KS | 1 |
| Tseng, CC | 1 |
| García Vicente, AM | 1 |
| Soriano Castrejón, Á | 1 |
| Alvarez Cabellos, R | 1 |
| Sanchez Gil, B | 1 |
| Mohedano Mohedano, N | 1 |
| Kwee, SA | 3 |
| Lim, J | 2 |
| Coel, MN | 3 |
| Caroli, P | 4 |
| De Giorgi, U | 4 |
| Scarpi, E | 3 |
| Fantini, L | 1 |
| Moretti, A | 2 |
| Galassi, R | 2 |
| Celli, M | 1 |
| Conteduca, V | 4 |
| Rossi, L | 2 |
| Bianchi, E | 2 |
| Paganelli, G | 4 |
| Matteucci, F | 4 |
| Salvi, S | 1 |
| Lolli, C | 1 |
| Burgio, SL | 3 |
| Menna, C | 3 |
| Schepisi, G | 1 |
| Testoni, S | 1 |
| Gurioli, G | 1 |
| Casadio, V | 1 |
| Vija Racaru, L | 1 |
| Sinigaglia, M | 1 |
| Kanoun, S | 1 |
| Ben Bouallègue, F | 1 |
| Tal, I | 1 |
| Brillouet, S | 1 |
| Bauriaud-Mallet, M | 1 |
| Zerdoud, S | 1 |
| Dierickx, L | 1 |
| Vallot, D | 1 |
| Caselles, O | 1 |
| Gabiache, E | 1 |
| Pascal, P | 1 |
| Courbon, F | 1 |
| Gomez-Iturriaga, A | 1 |
| Casquero Ocio, F | 1 |
| Ost, P | 1 |
| Fernandez, I | 1 |
| Rodeño, E | 1 |
| Llarena, R | 1 |
| Garcia-Olaverri, J | 1 |
| Ortiz de Zarate, R | 1 |
| Cacicedo, J | 1 |
| Ahtamon, A | 1 |
| Bilbao, P | 1 |
| Nozaki, K | 1 |
| Kawai, T | 1 |
| Fujimura, T | 1 |
| Matsui, H | 1 |
| Teshima, T | 1 |
| Oshina, T | 1 |
| Takahashi, A | 1 |
| Sato, Y | 1 |
| Yamada, D | 1 |
| Azuma, T | 1 |
| Hotta, M | 1 |
| Nakajima, K | 1 |
| Nakayama, H | 1 |
| Minamimoto, R | 1 |
| Kume, H | 1 |
| Watanabe, A | 1 |
| Kromer-Baker, K | 1 |
| Balogova, S | 1 |
| Zakoun, JB | 1 |
| Michaud, L | 1 |
| Khalil, A | 1 |
| Tassart, M | 1 |
| Esteso, A | 1 |
| Kerrou, K | 1 |
| Huchet, V | 1 |
| Carette, MF | 1 |
| Lotz, JP | 1 |
| Talbot, JN | 1 |
| Fabbri, F | 1 |
| Carretta, E | 1 |
| Amadori, D | 2 |
| Garcia Garzon, JR | 1 |
| Bassa, P | 1 |
| Soler, M | 1 |
| Moragas, M | 1 |
| Llinares, E | 1 |
| Riera, E | 1 |
| Ceci, F | 1 |
| Castellucci, P | 1 |
| Graziani, T | 1 |
| Schiavina, R | 1 |
| Renzi, R | 1 |
| Borghesi, M | 1 |
| Di Tullio, P | 1 |
| Brunocilla, E | 1 |
| Ardizzoni, A | 1 |
| Fanti, S | 1 |
| Maines, F | 1 |
| Caffo, O | 1 |
| Donner, D | 1 |
| Sperduti, I | 1 |
| Bria, E | 1 |
| Veccia, A | 1 |
| Chierichetti, F | 1 |
| Tortora, G | 1 |
| Galligioni, E | 1 |
| Lee, J | 1 |
| Sato, MM | 1 |
| Lee, KH | 1 |
| Scalzi, P | 1 |
| Baiocco, C | 1 |
| Genovese, S | 1 |
| Trevisan, A | 1 |
| Sirotova, Z | 1 |
| Poti, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Evaluation of SBRT in Oligometastatic Castration-Refractory Prostate Cancer and Immunogenicity of SBRT[NCT02816983] | 89 participants (Actual) | Observational | 2016-03-31 | Completed | |||
| Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer[NCT00928252] | Phase 1/Phase 2 | 25 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Measurement of Anti-Androgen Response Using Fluorine-18 Fluorocholine PET/CT in Androgen-Insensitive Prostate Cancer[NCT00928174] | Phase 1/Phase 2 | 27 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of patients achieving 30% or greater reduction in MATV measured on 18F-fluorocholine PET/CT (NCT00928252)
Timeframe: 21 to 98 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Received 18F-fluorocholine PET/CT | 20 |
PSA levels measured from the start of treatment over the period of follow-up were recorded. Time to PSA progression was calculated as the number of days from the start of treatment to the date of the first PSA test result that represented a 30% or greater increase from the PSA nadir, confirmed on the basis of repeated PSA measurements. For proportional hazards regression analysis, the percentage change in PSA level within 15 wk of starting treatment was calculated, using a 50% or greater decrease in PSA level as a predefined definition of PSA re- sponse based on Prostate Cancer Working Group guidelines. (NCT00928252)
Timeframe: Up to 15 week post-chemotherapy
| Intervention | Hazard Ratio (Number) |
|---|---|
| Positive Metabolically Active Tumor Response | 0.246 |
Time to PSA Progression between patients exhibiting MATV reduction greater or equal to 30% vs. MATV reduction less than 30%. (NCT00928252)
Timeframe: 2 years
| Intervention | days (Mean) | |
|---|---|---|
| MATV reduction > or = 30% | MATV reduction < 30% | |
| Received 18F-fluorocholine PET/CT | 194 | 116 |
The percentage of patients within a given prostate specific antigen range found to have at least one abnormal lesion demonstrating increased fluorine-18 fluorocholine uptake on positron emission tomography (PET) imaging consistent with the clinical diagnosis of metastatic or recurrent prostate cancer. (NCT00928174)
Timeframe: Concurrent with PET Procedure
| Intervention | %PET-positive cases in a given PSA range (Number) | |||
|---|---|---|---|---|
| PSA > 4 ng/mL (19 cases) | PSA 2-4 ng/mL (2 cases) | PSA > 0.5 - 2 ng/mL (1 cases) | PSA <= 0.5 ng/mL (0 cases) | |
| Single Arm | 100 | 100 | 100 | 0 |
1 review available for choline and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
Multimodality Imaging of Prostate Cancer.
Topics: Aged; Antigens, Surface; Carboxylic Acids; Choline; Cyclobutanes; Disease Progression; Fluorodeoxygl | 2019 |
4 trials available for choline and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in
Topics: Choline; Humans; Male; Orchiectomy; Positron Emission Tomography Computed Tomography; Prostatic Neop | 2021 |
Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Benzamides; Choline; Humans; Male; Middle Aged; Neoplas | 2018 |
Prognosis Related to Metastatic Burden Measured by ¹⁸F-Fluorocholine PET/CT in Castration-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Choline; Humans; Male; Middle Aged; Multimodal Imaging; Multivariate Analys | 2014 |
Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone.
Topics: Aged; Androstenes; Antineoplastic Agents; Choline; Disease-Free Survival; Drug Resistance, Neoplasm; | 2014 |
19 other studies available for choline and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
Tumor-Derived Extracellular Vesicles Predict Clinical Outcomes in Oligometastatic Prostate Cancer and Suppress Antitumor Immunity.
Topics: Choline; Extracellular Vesicles; Humans; Male; Prognosis; Prostatic Neoplasms, Castration-Resistant; | 2022 |
Radiographic paradoxical response in metastatic castrate-resistant prostate cancer (mCRPC) managed with new generation anti-androgens: a retrospective analysis.
Topics: Androgen Antagonists; Choline; Disease Progression; Docetaxel; Humans; Male; Positron Emission Tomog | 2022 |
Asymptomatic Metastasis to Thyroid Cartilage Detected by 18F-Choline and 64Cu-PSMA PET/CT as a Single Site of Disease Relapse in a Patient With Castration-Resistant Prostate Carcinoma.
Topics: Aged; Carcinoma; Choline; Copper Radioisotopes; Head and Neck Neoplasms; Humans; Male; Neoplasm Meta | 2020 |
The Relationship Between Total Lesion Activity on
Topics: Aged; Aged, 80 and over; Alpha Particles; Bone and Bones; Bone Neoplasms; Choline; Feasibility Studi | 2020 |
Assessment of the viability and treatment response of bone metastases in patients with metastatic castration-resistant prostate cancer using choline PET/CT.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Choline; Humans; Male; Middle Aged; Neoplasm Metasta | 2021 |
Response Detection of Castrate-Resistant Prostate Cancer to Clinically Utilised and Novel Treatments by Monitoring Phospholipid Metabolism.
Topics: Cell Line, Tumor; Cell Proliferation; Choline; Flutamide; Humans; Male; Paclitaxel; Phospholipids; P | 2017 |
Response Assessment of 223Ra Treatment: Should a Fluorocholine PET/CT Be Performed?
Topics: Aged; Bone Neoplasms; Choline; Humans; Male; Positron Emission Tomography Computed Tomography; Prost | 2017 |
Soft Tissue Response on 18F-Fluorocholine PET/CT in Metastatic Castrate-Resistant Prostate Cancer Treated With 223Ra-Dichloride: A Possible Abscopal Effect?
Topics: Aged, 80 and over; Choline; Disease Progression; Humans; Male; Neoplasm Metastasis; Positron Emissio | 2017 |
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Pr | 2017 |
Fluorine-18-fluorocholine PET/CT parameters predictive for hematological toxicity to radium-223 therapy in castrate-resistant prostate cancer patients with bone metastases: a pilot study.
Topics: Aged; Aged, 80 and over; Blood; Bone Neoplasms; Choline; Humans; Male; Middle Aged; Pilot Projects; | 2018 |
Outcomes after a first and/or second salvage treatment in patients with oligometastatic prostate cancer recurrence detected by (18-F) choline PET-CT.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Bone Neoplasms; Carcinoma; Choline; Fluori | 2019 |
Carbon 11-choline positron emission tomography/computed tomography and palliative local therapy for castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Carbon Radioisotopes; Choline; Humans; Longitudinal Studies; Male; Palliati | 2019 |
Whole-body 18F-fluorocholine (FCH) PET/CT and MRI of the spine for monitoring patients with castration-resistant prostate cancer metastatic to bone: a pilot study.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Choline; Fluorine Radioisotopes; Humans; Magnetic Resonance | 2014 |
Therapeutic Algorithm Guided by Sequential 11C-Choline PET/CT in a Patient With Metastatic Castration-Resistant Prostate Cancer.
Topics: Aged; Algorithms; Antineoplastic Agents; Carbon Radioisotopes; Choline; Humans; Male; Multimodal Ima | 2015 |
(18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Choline; Humans; Male; Middle Aged; Mult | 2015 |
(11)C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel.
Topics: Aged; Aged, 80 and over; Carbon Radioisotopes; Choline; Docetaxel; Humans; Male; Middle Aged; Multim | 2016 |
Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Bone Neoplasms; Choli | 2016 |
Prediction of PSA Progression in Castration-Resistant Prostate Cancer Based on Treatment-Associated Change in Tumor Burden Quantified by 18F-Fluorocholine PET/CT.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Cancer Vaccines; Choline; Combined Modality Thera | 2016 |
Prediction of PSA Progression in Castration-Resistant Prostate Cancer Based on Treatment-Associated Change in Tumor Burden Quantified by 18F-Fluorocholine PET/CT.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Cancer Vaccines; Choline; Combined Modality Thera | 2016 |
Prediction of PSA Progression in Castration-Resistant Prostate Cancer Based on Treatment-Associated Change in Tumor Burden Quantified by 18F-Fluorocholine PET/CT.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Cancer Vaccines; Choline; Combined Modality Thera | 2016 |
Prediction of PSA Progression in Castration-Resistant Prostate Cancer Based on Treatment-Associated Change in Tumor Burden Quantified by 18F-Fluorocholine PET/CT.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Cancer Vaccines; Choline; Combined Modality Thera | 2016 |
Evaluation of bone metastases by 18F-choline PET/CT in a patient with castration-resistant prostate cancer treated with radium-223.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Choline; Fluorine Radioisotopes; Humans; Male; Positron Emissi | 2017 |